Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies.

Cancer Drug Resist · 2023 · PMC10804393 · PMID 38263984

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

a positive trendP = 0.057so close (0.05 < p ≤ 0.1)

While the trial was negative for its primary endpoint of OS in all subgroups, there was a positive trend to survival benefit in patients with PD-L1 CPS ≥ 10 (12.7 vs. 11.6 months, HR 0.78; P = 0.057).

also in 3,956 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.